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1  | INTRODUCTION
In Japan, olanzapine (OLA) and quetiapine extended‐release 
(QUEXR) are approved for the treatment of bipolar depression.1 It 
is unknown, however, if one or the other antipsychotic is superior 
in terms of the risk‐benefit ratio for Japanese patients with this 
disorder. We reviewed phase 3 studies of each antipsychotic for bi‐
polar depression in Japan.
For OLA, a 6‐week, double‐blind, randomized, placebo‐con‐
trolled phase 3 trial (OLA, n = 343; placebo, n = 171) was conducted 
in Japan, China, Taiwan, Korea, and the United States of America.2 
This was a flexible‐dose study (5‐20 mg/d). Patients aged 18 to 
 
Received: 9 June 2019  |  Revised: 18 June 2019  |  Accepted: 24 June 2019
DOI: 10.1002/npr2.12070  
M I C R O  R E P O R T
Quetiapine extended‐release vs olanzapine for Japanese 
patients with bipolar depression: A Bayesian analysis
Taro Kishi1  |   Toshikazu Ikuta2 |   Yuki Matsuda3 |   Nakao Iwata1
This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in 
any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
© 2019 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Society of 
NeuropsychoPharmacology.
1Department of Psychiatry, Fujita Health 
University School of Medicine, Toyoake, 
Aichi, Japan
2Department of Communication Sciences 
and Disorders, Digital Neuroscience 
Laboratory, The University of Mississippi, 
University Park, Mississippi, USA
3Department of Psychiatry, Jikei University 
School of Medicine, Minato‐ku, Tokyo, Japan
Correspondence
Taro Kishi, Department of Psychiatry, Fujita 
Health University School of Medicine, 1‐98 




Objective:  It is unknown whether there are differences in efficacy and safety be‐
tween quetiapine extended‐release, 300 mg/d (QUEXR300), and olanzapine, 
5‐20 mg/d (OLA), for Japanese patients with bipolar depression.
Methods: We conducted a Bayesian analysis of data from phase 3 studies in Japan 
of QUEXR300 and OLA. Outcomes were remission rate (primary), response rate, 
improvement on the Montgomery‐Åsberg Depression Rating Scale and 17‐item 
Hamilton Depression Rating Scale scores, discontinuation rate, and incidence of in‐
dividual adverse events. We calculated the standardized mean difference (SMD) and 
the risk ratio (RR) and 95% credible interval (95% CrI) for continuous and dichoto‐
mous data, respectively.
Results: There were no significant differences between QUEXR300 and OLA for any 
of the efficacy outcomes. QUEXR300 was associated with a higher incidence of som‐
nolence than OLA (RR = 5.517; 95% CrI = 1.563, 19.787), while OLA was associated 
with greater increase body weight (SMD = −0.488; 95% CrI = −0.881, −0.089) and 
blood prolactin levels (SMD = −0.642; 95% CrI = −1.073, −0.213) than QUEXR300, 
and a greater decrease in high‐density lipoprotein cholesterol levels (SMD = −0.408; 
95% CrI = −0.785, −0.030) than QUEXR300.
Conclusion: Although the two drugs’ efficacy did not differ, OLA increased the risk 
of metabolic syndrome and QUEXR300 the risk of somnolence. A large scale, long‐
term, head‐to‐head comparison study of QUEXR300 vs OLA for Japanese patients 
with bipolar depression is needed to confirm the results of the current study.
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64 years with bipolar I disorder who were acutely depressed were 
recruited. Inclusion criteria were as follows: a depressive episode 
for ≤ 90 days at the time of randomization, a total score ≥ 18 on the 
17‐item Hamilton Rating Scale for Depression (HAMD‐17),3 and a 
history of ≥ 1 manic or mixed episode in the previous 6 years, but 
not currently having a manic episode (Young Mania Rating Scale 
[YMRS]4 total score ≤ 8 at randomization). The primary outcome 
of the study was the change from mean baseline to study endpoint 
in the Montgomery‐Åsberg Depression Rating Scale (MADRS)5 
score. Although OLA was superior to placebo in terms of im‐
proved MADRS score and response (defined as a ≥ 50% reduction 
in MADRS at endpoint) rate, there was no significant difference 
in remission (defined as a MADRS total score ≤ 12) rate between 
the groups. Compared with placebo, OLA was associated with a 
higher incidence of somnolence, sedation, significant weight gain 
(≥7% body weight), and increased appetite. Patients taking OLA 
also had significantly increased total cholesterol, triglyceride, and 
low‐density lipoprotein (LDL) cholesterol levels. An analysis was 
also conducted of the Japanese subpopulation in this study (OLA, 
n = 104; placebo, n = 52).6 Although OLA was superior to placebo in 
terms of an improved MADRS score, there were no significant dif‐
ferences in rates of response (same definition as the primary anal‐
ysis) or remission (same definition as the primary analysis) between 
OLA and placebo. In the Japanese subgroup, compared with pla‐
cebo, OLA was associated with a higher incidence of somnolence 
and significant weight gain (≥7% body weight) and significantly in‐
creased total cholesterol, triglyceride, and LDL cholesterol levels, 
along with significantly decreased high‐density lipoprotein (HDL) 
cholesterol levels. Thus, there were differences in some of the ef‐
ficacy and safety outcomes between the primary and the Japanese 
subpopulation analyses.
An 8‐week, double‐blind, randomized, placebo‐controlled 
phase 3 trial of QUEXR was conducted in Japan.7 This was a 
fixed‐dose study comparing QUEXR at 300 mg/d (QUEXR300, 
n = 179), at 150 mg/d (QUEXR150, n = 74), and placebo (n = 177). 
The investigators discontinued recruitment to the QUEXR150 
arm because of difficulty in finding enough patients. Therefore, 
efficacy outcomes for QUEXR150 were not reported. Patients 20 
to 64 years old with bipolar I disorder or bipolar II disorder who 
were acutely depressed were recruited. Inclusion criteria were a 
HAMD‐17 total score ≥20, a HAMD‐17 depressed mood score 
≥2 points, a YMRS total score <13, and <9 mood episodes within 
12 months prior to informed consent. The primary outcome of the 
study was the mean change from baseline to study endpoint in 
the MADRS score. QUEXR300 was superior to placebo in improv‐
ing the MADRS score and rates of response (same definition as 
the OLA study) and remission (same definition as the OLA study). 
QUEXR300 was associated with a higher incidence of somnolence 
and dry mouth than placebo.
No head‐to‐head study of QUEXR300 vs OLA has been con‐
ducted to assess efficacy and safety among Japanese patients with 
bipolar depression. Therefore, we conducted a Bayesian analysis 
of data from both the Japan OLA and QUEXR phase 3 studies to 
compare the efficacy and safety of the two drugs in Japanese pa‐
tients with bipolar depression (Appendix S1).
2  | METHODS
2.1 | PICO
Patients with bipolar depression who were not being treated with 
any mood stabilizers or antipsychotics at baseline were eligible. The 
intervention groups were given OLA or QUEXR300, and the control 
group was given placebo. The outcomes were efficacy and safety/
tolerability (detailed information in the following section).
2.2 | Data synthesis
Two authors (T.K. and Y.M.) extracted data from the articles and 
entered it into a spreadsheet. The primary outcome of remission 
was defined as a MADRS score ≤12. The secondary outcomes in‐
cluded response (≥50% reduction in the MADRS score from baseline 
to endpoint) rate, an improvement in MADRS and HAMD‐17 total 
scores from baseline, all‐cause discontinuation, discontinuation due 
to adverse events, and individual adverse events. Only intention‐to‐
treat population data were used in the analysis. For the OLA study, 
we used only data from the Japanese patients. The algebraic signs 
of the values of HDL cholesterol were reversed, as a decrease in the 
HDL cholesterol level indicates a worse response.
2.3 | Statistical analysis
A Bayesian analysis was conducted using the GeMTC package in R 
Statistics software.8 We used a fixed effects model for this study 
because a random effects model might be too conservative for this 
small a Bayesian analysis. We calculated the standardized mean dif‐
ference (SMD) and the risk ratio (RR) and 95% credible interval (95% 
CrI) for continuous and dichotomous data, respectively. The number 
of burn‐in iterations, the number of interface iterations, and thinning 
factor were set at 5000, 20 000, and 10, respectively.
3  | RESULTS
3.1 | Study characteristics
The two studies were double‐blind, randomized, placebo‐controlled 
trials sponsored by pharmaceutical companies and were published 
in English. The methodological quality of both studies was high as 
assessed with the Cochrane Risk of Bias Tool.
3.2 | Results of Bayesian analysis
There were no significant differences between QUEXR300 and 
OLA in any of the efficacy outcomes (Table 1). Although QUEXR300 
was associated with a higher incidence of somnolence than OLA 
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(RR = 5.517; 95% CrI = 1.563, 19.787), OLA was associated with 
greater increase body weight (SMD = −0.488; 95% CrI = −0.881, 
−0.089) and blood prolactin levels (SMD = −0.642; 95% CrI = −1.073, 
−0.213) than QUEXR300, and a greater decrease in HDL cholesterol 
levels (SMD = −0.408; 95% CrIs = −0.785, −0.030) than QUEXR300.
4  | DISCUSSION
We conducted a Bayesian analysis of QUEXR300 compared with 
OLA in terms of efficacy and safety outcomes for Japanese patients 
with bipolar depression. We did not detect any differences in ef‐
ficacy between the two drugs. However, OLA had a greater risk 
than QUEXR300 of weight gain and decreased HDL cholesterol 
levels compared with QUEXR300. On the other hand, QUEXR300 
had a greater risk of somnolence than OLA. A recent systematic re‐
view noted that if patients took QUEXR300 orally once daily in the 
evening rather than at bedtime, the incidence of somnolence would 
decrease.9
The study has several limitations. First, the differences in the 
characteristics of the patients (diagnosis: OLA = bipolar I disorder, 
QUEXR300 = bipolar I disorder or bipolar II disorder) and the stud‐
ies (duration of study [6 weeks study vs 8 weeks study] and dos‐
ing effect [flexible‐dose study vs fixed‐dose study]) included in this 
study might influence the results of our study. However, we did not 
examine whether those clinical factors were associated with the re‐
sults of the study (for example, somnolence) because the number 
of studies and of patients analyzed was small. Secondly, both stud‐
ies included in the analysis were industry sponsored, so the possi‐
bility of sponsorship bias should be considered when interpreting 
our results.10 Thirdly, this study did not evaluate several common 
adverse events such as extrapyramidal symptoms, constipation, or 
dry mouth because there were insufficient data for analysis. Finally, 
both trials had a short duration. A large scale, long‐term, head‐to‐
head comparison of QUEXR300 vs OLA for Japanese patients with 
bipolar depression is needed to confirm the results of the current 
study.
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TA B L E  1   Bayesian analysis: QUEXR300 vs OLA
RR (95% CrI)a
Remission rate 0.786 (0.478, 1.257)
Response rate 1.109 (0.769, 1.577)
All‐cause discontinuation 1.044 (0.476, 2.276)
Discontinuation due to adverse events 1.089 (0.277, 3.654)
Significant weight gain (≥7% body 
weight)
0.251 (0.009, 2.573)
Somnolence 5.517 (1.563, 19.787)
SMD (95% CrI)b
MADRS 0.189 (−0.245, 0.626)
HAMD‐17 0.283 (−0.114, 0.681)
Body weight −0.488 (−0.881, −0.089)
Fasting blood sugar −0.114 (−0.517, 0.291)
Serum triglycerides −0.011 (−0.407, 0.390)
Serum total cholesterol −0.086 (−0.483, 0.314)
Serum HDL cholesterol −0.408 (−0.785, −0.030)
Serum LDL cholesterol −0.172 (−0.575, 0.230)
Blood prolactin −0.642 (−1.073, −0.213)
Abbreviations: 95% CrI, 95% credible interval; HAMD‐17, 17‐item 
Hamilton Rating Scale for Depression; HDL cholesterol, high‐density 
lipoprotein cholesterol; LDL cholesterol, low‐density lipoprotein choles‐
terol; MADRS, Montgomery‐Åsberg Depression Rating Scale; RR, risk 
ratio; SMD, standardized mean differences.
aRR < 1 favors QUEXR300; RR > 1 favors OLA. 
bNegative SMD values favor QUEXR300; positive SMD values favor 
OLA. 
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